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Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral 
pain involving predominantly the shoulders and proximal aspects of the arms and less 
commonly the neck and the pelvic girdle. This review discusses briefly the main 
epidemiological data and clinical features of this condition. Especial attention is paid in 
the management of the disease. For this reason, both the classic management and the 
impact of new therapies are discussed in depth. In general, patients with PMR 
experience a rapid response to 12.5-25 mg/prednisone/day in less than a week. Patients 
with poor response to glucocorticoids or with relapsing disease require other therapies 
aimed mainly to spare glucocorticoids. Among them, methotrexate is the most 
commonly used. Nevertheless, different studies indicate that this agent yields only a 
modest effect. Biologic therapies against the main cytokines involved in the 
pathogenesis of the disease have been used in refractory patients. However, randomized 
controlled trials do not support the use of anti-tumor necrosis factor agents in PMR. In 
contrast, several case series and retrospective studies highlight the efficacy of the anti-
interleukin-6 receptor tocilizumab in PMR. Nonetheless, controlled trials are needed to 
fully establish the beneficial effect of this agent. The potential favorable effect of the 
Janus-kinase inhibitors and new anti-interleukin-6 antagonists remains to be 
determined. 
 
Keywords: Polymyalgia rheumatica, glucocorticoids, methotrexate, DMARD, biologic 
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Polymyalgia rheumatica (PMR) is a common inflammatory disease of unknown 
etiology affecting especially elderly people from Western countries, characterized by 
severe pain and stiffness involving the shoulders, proximal aspects of the arms, neck, 
pelvic girdle and proximal aspects of the thighs. Patients with PMR have morning 
stiffness lasting typically more than 45 minutes as well as non-specific symptoms such 
as fatigue and malaise (1,2). Typically, patients with PMR have elevation of acute phase 
reactants, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 
(1,3).  
PMR is rarely observed in individuals younger than 50 years (2). Women are affected 
two to three times more often than men. The incidence rate increases progressively with 
age in both sexes until the age of 80 years (4). The highest incidence is in people older 
than 65 years, particularly between ages 70 and 80 (2).  
PMR is more common in Scandinavian countries and in people of Northern European 
descent (5,6). The annual incidence of PMR for individuals older than 50 years in the 
period 1985-1997 in Göteborg (Sweden) was 50/100,000 (7). Similarly, data from the 
Olmsted County (Minnesota, USA) showed an annual incidence of 63.9/100,000 
inhabitants aged 50 years and older (4). By contrast, a lower incidence of PMR has been 
observed in Southern Europe countries (8,9). In this way, the annual incidence of PMR 
in Italy and Spain was reported as 12.7/100,000 and 18.7/100,000 population aged 50 
years and older, respectively (8,9).  
The prevalence of PMR is also higher in Northern European populations. Recent data 
from Olmsted County have shown that the overall age and sex adjusted prevalence rate 
of PMR was 701/100,000 people (870 in women and 508 in men /100,000 people) (10), 
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while the prevalence of PMR in UK was 910/100,000 inhabitants (1040 in women and 
780 in men/100,000 people) (11).   
The susceptibility for suffering PMR is a result of the interaction between genetics and 
unknown environmental factors (12). In fact, a possible association with different 
infections such as mycoplasma pneumoniae, parvovirus B19 and chlamydia pneumonia 
has been described (6). Regular fluctuations and seasonal variations in the incidence of 
disease throughout the year supports this hypothesis (13,14).  
PMR is frequently associated with giant cell arteritis (GCA), the most common 
vasculitis in elderly people in Western countries, that mainly involves the large and 
medium arteries, especially the branches of the proximal aorta (1,3,15). Furthermore, 
both entities respond well and quickly to glucocorticoids (GCs). 
 
2. Pathophysiology  
PMR as a disease mainly involving extra-articular synovial structures at shoulders and 
hips. Although both joints and periarticular tissues can be involved in patients with 
PMR, arthritis is usually mild and typically non-erosive, explaining only partially the 
symptomatology of these patients (16). By contrast, a clear inflammation of peri-
articular tissue and synovial bursae such as the subacromial/subdeltoid (SAD) bursa, 
usually associated with tenosynovitis of the biceps (Figure 1), the trochanteric and 
iliopsoas bursae, and the cervical or lumbar interspinous bursae, has been demonstrated 
using different imaging techniques such as ultrasonography (US), scintigraphy, 
magnetic resonance imaging (MRI) and positron emission tomography integrated with 
computed tomography (PET/CT) (17,18). This soft-tissue inflammation would explain 
much better many of the musculoskeletal manifestations and the pain that PMR have at 
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proximal level of the extremities (18). In fact, some authors have suggested that PMR 
may be a disorder predominantly involving the extra-articular synovial structures (19).  
Arthroscopic studies have also shown the presence of mild synovitis in the proximal 
joints of patients with PMR. The inflammatory infiltrate found in the shoulder synovial 
membranes and other involved joints was composed mainly of macrophages and CD4 T 
lymphocytes (20).  
Interestingly, evidence of subclinical arterial inflammation, including activated dendritic 
cells, interleukin (IL)-1 and IL-6, can also be detected in the temporal arteries of some 
patients with PMR without evidence of GCA (21). However, unlike GCA, interferon 
gamma (INF-ϒ)-producing T cells are not prominent in PMR. On the contrary, 
proinflammatory cytokines may have an important role in PMR. Increased interstitial 
concentrations of IL-1α/β, IL-1 receptor antagonist, IL-6, IL-8, tumor necrosis factor α 
(TNF-α), and monocyte chemoattractant protein 1 have been detected in symptomatic 
muscles of patients with PMR when compared with controls (22).  
At the cellular level, a decrease in the regulatory T (Treg) cells and marked shift in the 
Th17 cell/Treg cell balance towards an increased Th17 cell response occurs in PMR 
(23). In newly diagnosed PMR patients, there is an inverse correlation between the 
number of lymphocyte B cell and the ESR, CRP and serum B-cell activating factor 
(BAFF) levels (24). In addition, patients recently diagnosed with GCA or PMR exhibit 
decreased numbers of circulating B cells compared to healthy controls (24). 
 
3. Clinical manifestations  
Patients with PMR are generally older than 50 years and they present with pain and 
stiffness in the shoulders as well as in the proximal aspects of the arms, neck, pelvic 
girdle and thighs, usually bilateral. The disease has a rapid onset, generally in a few 
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days. Morning stiffness last typically > 45 minutes in the involved areas, improves 
progressively over the day and worsens after rest (1,25,26). Constitutional symptoms 
such as asthenia, anorexia and weigh loss along with low-grade fever are frequent (1). 
Painful restriction of active movement is also often observed. Other findings include 
muscle tenderness, peripheral non-erosive arthritis predominantly involving the knees 
and wrists, carpal tunnel syndrome, distal extremity swelling with pitting edema and 
distal tenosynovitis (16). In some cases, the clinical picture may be similar to that observed in 
patients with remitting seronegative symmetrical synovitis with pitting edema (RS3PE) 
syndrome (27,28). Table 1 summarizes the main clinical features observed in patients 
with PMR. 
Patients with PMR typically have increase of acute phase reactants. Indeed, ESR and 
CRP are generally greater than 40 mm/1st hour and 6 mg/L, respectively (1,26). 
However, some patients may present with low ESR and CRP (29), and in these cases 
other conditions mimicking PMR should be excluded (1,26). Other nonspecific 
laboratory abnormalities such as increased levels of α-2 globulin proteins, anemia, 
thrombocytosis and hypoalbuminemia can also be found (30). On the contrary, anti-
cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), antinuclear 
antibodies and anti-neutrophil cytoplasmic antibodies are generally negative (1). 
 
4. Diagnosis of PMR 
The diagnosis of PMR is supported by a clinical history, physical examination and the 
assessment of routine laboratory markers of inflammation (15,31-33). New onset 
headache, scalp tenderness or visual manifestations may indicate that PMR is associated 
with GCA. In fact, PMR may be the initial manifestation in patients with GCA. Indeed, 
most studies indicate that the frequency of patients with PMR who have associated 
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GCA is around 15-20% (15,34,35). Nonetheless, in some series of GCA patients in 
whom the diagnosis was confirmed by a positive temporal artery biopsy, the frequency 
of PMR was up to 40%-50% of the cases (36). Patients with isolated PMR have in 
general lower values of ESR and less frequently anemia and thrombocytosis than those 
with PMR associated with GCA (37). 
However, and although the diagnosis of PMR in typical cases is not difficult, there are 
no specific tests to make a diagnosis of PMR nowadays. Because of that, the diagnosis 
is usually based on classification criteria (1). In 2012, the European League Against 
Rheumatism (EULAR) together with the American College of Rheumatology (ACR) 
established a new classification criteria, remarking the relevance of polymyalgia hip 
involvement, the absence of pain in other joints as well as negative results for anti-CCP 
antibodies and RF (38). These criteria also include for first time the use of US to detect 
bilateral SAD bursitis and/or trochanteric bursitis (38). Other authors have included a 
rapid response to glucocorticoids (GCs) as an important criterion for the diagnosis of 
PMR, although this is nonspecific and it has not been incorporated in the 2012 
EULAR/ACR criteria. 
In atypical cases, the clinician must establish the differential diagnosis with other 
systemic diseases and/or malignancy, particularly in patients who do not respond to 
GCs (1,26,39). 
 
5. Imaging studies in PMR 
Ultrasonography, MRI and PET/CT have been used in PMR to detect synovitis in 
proximal joints and extra-articular structures and may help with the diagnosis of the 
disease. Indeed, US and MRI are useful and equally effective to confirm the presence of 
bursitis in patients with PMR (40-42) (Figure 1). 
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18F-fluorodeoxyglucose (FDG) PET/CT have observed FDG accumulation at the level 
of spinous processes at cervical and lumbar spine in around one-half of PMR patients 
(43). In general, FDG uptake is associated with interspinous bursitis and it is more 
commonly observed in the lumbar spine than in the cervical region.  
Finally, PET/CT has revealed to be especially useful to disclose the presence of vascular 
involvement associated with PMR. Blockmans et al. showed that about one third of 35 
patients with isolated PMR had increased vascular FDG uptake, typically in the 
subclavian arteries. Nevertheless, uptake intensity was less than that seen in GCA (44). 
 
6. Treatment of PMR 
6.1. Glucocorticoids: the cornerstone in the treatment of PMR  
The main goals of the treatment of PMR are to control the disease and prevent relapses. 
To achieve these goals, oral prednisone/prednisolone constitutes the keystone of the 
treatment in PMR (39,45,46). The reasons for the successful effect of GCs in PMR are 
multiple and are based on their strong antiinflammatory and immunosuppressive 
properties. In particular, GCs exert their main anti-inflammatory/immunosuppressive 
effects primarily on leucocytes and secondary immune cells, where their functions as 
well as their distribution are affected. More specifically, GCs exert their main effects 
through genomic and non-genomic mechanisms, resulting in their typical therapeutic 
effects and contributing to its final anti-inflammatory efficacy.  
The initial dose of prednisone/prednisolone recommended by the EULAR/ACR 
guidelines ranges between 12.5-25 mg/day (45,47). However, this dose must be 
individualized to every case. Thus, patients with diabetes or osteoporosis would start 
with a dose between 12.5-15 mg/day (1) while very symptomatic people without these 
risk factors could receive a starting dose of 20-25 mg/day. The EULAR/ACR 
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recommendations for the management of PMR suggest using a single dose of GCs 
(45,47). Nevertheless, in our experience a divided dose of prednisone at the onset of 
treatment may help to a quicker improvement of the symptoms, especially in patients 
with in patients with very active clinic (1). With this strategy, patients usually 
experience improvement in a 1-2 weeks, commonly within the first 72 hours (46,48). In 
general, the clinical improvement is associated with a normalization of acute phase 
reactants, normally within 2-4 weeks after the onset of therapy (25,46).  
Regarding GC tapering (49) there is not a standardized approach on how they should be 
removed in patients with PMR in remission (50). In our experience, we maintain the 
initial prednisone dose for 3-4 weeks and then we taper it progressively whenever the 
response has been favorable. In those in whom we start treatment with a prednisone 
dose of 15 mg/day, our tapering scheme is 12.5 mg daily for 2-4 weeks, 10 mg daily for 
4-6 weeks and then we reduce the dose by 1-1.25 mg/month or 2.5 mg every 2-3 
months (1) (Table 2).  
Although experts support the use of prednisone or prednisolone for the treatment of 
PMR, some studies assessed the role of deflazacort in the management of these patients 
(51,52). However, deflazacort was found to be less potent than prednisone/prednisolone 
when used at equivalent doses (51,52). By contrast, modified-release prednisone has 
shown greater percentages of complete responders than for immediate-release 
prednisone (53.8% vs. 40.9% respectively) in early PMR at 4 weeks of treatment (53). 
The use of intramuscular (IM) methylprednisolone acetate (120 mg every 2 weeks for 
12 weeks followed by monthly injections with dose reductions of 20 mg every 3 
months) was less effective than an initial dose of 15 mg/oral prednisolone/day and led 
to lower rates of discontinuation of the therapy (54).  
Table 3 shows the main adverse effects of the chronic use of corticosteroids.  
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Non-steroidal anti-inflammatory drugs are of little value in the management of PMR, 
and increase the risk of gastrointestinal or renal complications. 
6.2. Glucocorticoid-sparing agents 
Either conventional immunosuppressive drugs or biologic agents have be used in 
patients with PMR requiring prolonged GC therapy due to refractory or relapsing 
disease with the objective of stopping GCs at some point in the evolution and avoid the 
appearance of adverse effects.  
Methotrexate (MTX) either oral or parenteral (subcutaneous/intramuscular) is the most 
used drug in the PMR as a GC-saving agent. MTX is a folate antimetabolite that inhibits 
DNA synthesis, repair, and cellular replication. It acts intra-cellular by irreversibly 
binding to and inhibiting dihydrofolate reductase, inhibiting the formation of reduced 
folates, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid 
synthesis. MTX yields reduced monocytic cell activation, decreased IL-1 and IL-6 
secretion, inhibition of cyclo-oxygenases synthesis, neutrophil chemotaxis and adhesion 
molecules expression (55). These effects may explain the antiinflammatory role of 
MTX in PMR. The initial dose of MTX generally ranges between 10 to 15 mg/week 
(46,48). Some studies have shown no benefit whereas others indicate that MTX may be 
useful to reach clinical remission and decrease the number of relapses (56-58). Van der 
Veen et al. carried out a randomized double blind, placebo-controlled study in 40 
patients with PMR, six of them with clinical features of GCA (56). The study did not 
show any additional benefit of the association of oral MTX to prednisone after 2 years 
of follow-up (time to and duration of remissions, number of relapses, or cumulative 
prednisone doses). However, the MTX dose in this study was very low (7.5 mg/week 
orally) (56). It is possible that higher doses of MTX given subcutaneously, would have 
been more appropriate to assess if MTX is useful as a GC-sparing agent in PMR. In 
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another study, Caporali et al. assessed the efficacy and safety of prednisone in 
combination with oral MTX versus prednisone alone in patients with newly diagnosed 
PMR (57). Specifically, these authors evaluated the percentage of PMR patients no 
longer taking prednisone, the number of relapses, and the cumulative prednisone dose 
after 76 weeks of treatment. The study protocol recommended reducing the dose from 
25 mg/day up to 0 at 24 weeks of treatment. Oral MTX (10 mg/week) or placebo were 
given weekly for 48 weeks. Remarkably, 87.5% of the patients from the MTX group 
(28 of 32 patients) had stopped of taking prednisone at 76 weeks. The median 
cumulative prednisone dose in PMR patients treated with MTX was 2.1 g vs. 3.0 g for 
patients taking prednisone alone (57). In addition, patients undergoing MTX therapy 
had a significant reduction in the number of relapses when compared to those receiving 
prednisone plus placebo. These results supported the use of oral MTX (10 mg/week) in 
the management of PMR (57). 
Another prospective study performed by Ferraccioli et al. evaluated the potential 
beneficial effect of IM MTX in patients with PMR (58). In this study, 24 patients 
recently diagnosed of PMR were randomized to receive 10 mg/week of IM-MTX plus 
prednisone, or prednisone alone. At month 12 all patients were in clinical remission in 
both arms of the study (58). However, the cumulative prednisone dose was significantly 
lower in the MTX treated group than in the placebo group. Unlike those from the MTX 
group, patients receiving placebo showed a reduction in the bone mineral density (58). 
Therefore, although the efficacy of MTX in the management of PMR is still 
controversial, the 2015 EULAR/ACR recommendations for the management of PMR 
support the use of this drug in patients with inadequate response to GCs, in those with 
relapses and in patients experiencing GC‐ related adverse events (47) (Table 3).  
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The use of other conventional DMARDs is more anecdotal. De Silva et al. conducted a 
double-blind randomized placebo-controlled study to assess the efficacy of azathioprine 
(AZA) as a GC-sparing agent in 31 patients with PMR, GCA or both conditions (59). In 
fact, patients treated with AZA had a lower GC requirement. However, the number of 
patients included in this study was relatively small and almost a third from them met 
definitions for GCA (59). Moreover, the relatively high frequency of side effects 
observed in the study does not support the use of AZA for this indication.  
Likewise, hydroxychloroquine was not found useful in PMR patients when compared to 
GCs alone (60). Regarding the use of leflunomide, a small series of difficult-to-treat 
patients with GCA (n=11) and PMR (n=12) were retrospectively assessed by 
Diamantopoulos et al. (61). Leflunomide-treated patients with PMR had CRP reduction 
of 6 mg/dL and showed 3.7 mg reduction in prednisolone dose (61). Although these 
results suggest that leflunomide may be useful in PMR therapy, further information is 
needed to support its use as a GC sparing agent in PMR. Furthermore, potential 
hepatotoxicity of leflunomide in elderly may be a concern, as this drug has a black box 
warning for liver injury, especially in arthritis patients or ageing people with pre-
existing liver disease, elevated liver enzymes or patients who are taking other drugs that 
can cause liver injury (https://www.fda.gov/Drugs/DrugSafety/ucm218679.htm). 
6.3. Biologic therapies in PMR 
Studies of biologic treatment in isolated PMR are scarce, and most of them are carried 
out in PMR associated with GCA. TNF-α antagonists were the first biologic agents used 
in both GCA and PMR, either as monotherapy (in PMR) or in combination with GCs 
(in PMR plus GCA). Initial studies based on single cases or small series revealed 
encouraging results (62), particularly in patients with diabetes mellitus and osteoporosis 
(63). However, data from more rigorous studies, including randomized control trials, did 
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not support the initial results (64-68). In this regard, the only randomized clinical trial 
on the efficacy of infliximab in PMR did not disclose additional benefit in newly 
diagnosed patients with PMR (69). Another randomized control trial with etanercept in 
monotherapy versus placebo in patients with PMR did not meet primary or secondary 
end points either (70). Based on these poor results, the 2015 EULAR/ACR 
recommendations did not support the use of anti-TNF drugs for the management of 
isolated PMR (47). 
IL-6 is a pleiotropic pro-inflammatory cytokine produced by a number of cells 
including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in different 
physiological processes such as T-cell activation, induction of immunoglobulin 
secretion, induction of hepatic acute phase protein synthesis and stimulation of 
hemopoiesis. IL-6 has been implicated in the pathogenesis of a broad spectrum of 
diseases including inflammatory diseases, and also in the pathogenesis of PMR (71,72). 
In fact, since the decrease of IL-6 in serum was associated with a reduction in disease 
activity, the blockade of IL-6 has been considered as a plausible therapeutic option in 
PMR, similarly that it has happened with the GCA (73). Tocilizumab (TCZ) is a 
monoclonal antibody that competitively inhibits the binding of IL-6 to its receptor. The 
inhibition of the entire receptor complex prevents IL-6 signal transduction to 
inflammatory mediators that convene B and T cells (74). 
Retrospective studies (75,76) and prospective clinical trials (77,78) indicate that the 
anit-IL-6 receptor TCZ is useful in GCA. In addition, many of the patients with GCA 
included in these studies also had PMR manifestations that improved quickly following 
the use of this biologic agent. Furthermore, preliminary data in PMR patients with poor 
response or unacceptable GC-induced adverse effects indicate that TCZ may be 
effective in these patients (79,80) (Table 3). A prospective open-label study including 
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20 patients with active recent-onset PMR who received three TCZ infusions at 4-week 
intervals showed clinical improvement of PMR symptoms at 12 weeks of follow-up 
(81). In another study, 10 patients with recently diagnosed PMR were included in a 
prospective open-label phase IIa trial with TCZ (82). In this study, patients were given 
intravenous TCZ (8 mg/kg/month) for 1 year, getting a rapid tapering of GCs according 
to a standardized protocol. Patients with PMR who declined to receive TCZ or who did 
not fulfill the inclusion criteria were used as a control group. Interestingly, in 9 of the 10 
TCZ-treated patients, relapse-free remission without GCs was achieved at 6 months 
(82). Furthermore, patients were able to discontinue GCs within 4 months of study 
entry. Persistent remission was also obtained in these patients throughout the entire 15-
month study. On the contrary, none of the PMR patients used as controls reached GC-
free remission at 6 or 12 months. Besides, 60% of the PMR patients from the control 
group suffered relapses (82). In addition, the mean cumulative prednisone dose was 
twice lower in TCZ-treated (1,085 mg) than in the control group (2,562 mg) (82). These 
results support the use of TCZ as GC-sparing agent in patients with active PMR. 
Interestingly, TCZ has recently been approved by the US FDA for treating GCA, a 
condition that is often associated with PMR 
(https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm559791.htm). 
However, TCZ has not been approved for the treatment of patients with isolated PMR 
yet. 
TCZ was also effective in patients with aortitis, some of them presenting as isolated 
PMR, refractory to prednisone and in most cases to conventional DMARDs (83). Table 
2 and Figure 2 summarize the main therapeutic steps in the treatment of PMR.  
Experience on the use of other biologic agents in patients with PMR is very limited.  
  
Biochem Pharmacol Treatment of PMR Castañeda et al 
16 
 
IL-1 and IL-17 are two important proinflammatory cytokines involved in the 
pathogenesis of this disease (23,71). In this line, secukinumab and canakinumab, two 
antagonists of these pathways have been proved, in a two-week single-blind, 
randomized 3-arm proof of concept study, in patients with PMR (84). Secukinumab is a 
human IgG1 monoclonal antibody binding interleukin-17A, while canakinumab is a 
human monoclonal antibody targeted at interleukin-1β. In that study, a rapid 
improvement of pain was observed in the GC-treated patients. However, only moderate 
improvement of movement was found in those PMR patients treated with secukinumab 
or canakinumab (84). Therefore, the use of these agents in patients with isolated PMR 
requires further research (Figure 2).  
Abatacept, a dimeric fusion protein that inhibits the interaction of CD80/CD86 
molecules with CD28 leading to a decrease of T cell activation, has been used in GCA 
(85), but data about its use in PMR have not been published up to date.  
Currently, a trial in phase III on sarilumab, another IL-6R antagonist, is being carried 
out. Primary results obtained with this agent will be presented on April 2021 
(NCT03600818).  
6.4. Small molecules: JAK/STAT inhibitors 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
pathway is a path strongly implicated in the cellular regulation in humans. In this stage, 
a broad spectrum of cytokines that are implicated in the pathogenesis of autoimmune 
diseases use this pathway to transduce intracellular signals (86,87). As well, several 
polymorphisms of JAK and STAT genes have been associated with different 
autoimmune diseases (86). In addition, high concentrations of interferon-gamma (IFN-
γ) mRNA have been found in the temporal arteries of patients with GCA with severe 
ischemic complications (86). The JAK/STAT-inhibitor tofacitinib, a kinase inhibitor for 
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JAK3 and JAK1, prevented T cell accumulation in the vessel wall and suppressed IFN-γ 
production and signaling by this pathway (87). Tofacitinib also yielded a marked 
reduction of the blood levels of IFN-γ in an experimental model of vasculitis in mice 
(88). Unfortunately, unlike GCA, there are no animal models of PMR to date that allow 
us to corroborate these data. Currently, there are one phase 2 trial and another phase 3 
evaluating the effect of baricitinib (ClinicalTrials.gov Identifier NCT03026504) and 
upadacitinib (ClinicalTrials.gov Identifier NCT03725202) in patients with relapsing 
GCA whose results are promising. Based on the close association between GCA and 
PMR, it is possible that JAK inhibition might also have a role in the treatment of 
patients with PMR in the future (87) (Figure 2). 
6.5. Future perspectives in PMR therapy 
Optimizing the benefit/risk ratio of GCs to minimize adverse events while achieving 
sustained remission is an ongoing challenge (71,89,90). Therefore, the development of 
innovative GC preparations and/or glucocorticoid receptor ligands might increase the 
benefit/risk ratio of GCs. In this line, selective GC receptor agonists and modulators 
(SEGRMs) may be promising drugs aimed to enhance anti-inflammatory cellular 
pathways selectively. In consequence, these drugs would avoid the activation of 
mechanisms associated with adverse effects related to these agents (91).  
Also, GCs can be selectively delivered in inflamed tissues using very-small, nanometre-
sized liposomes (92). Liposomes have been studied as drug delivery systems in the 
therapy of RA. Its applicability to other inflammatory conditions such as PMR may be 
possible in a near future. Finally, modified-release prednisone was shown to permit 
optimal chronotherapy with bedtime administration and the release of prednisone at the 
optimal time for suppression of pro-inflammatory cytokines (that is, around 2 a.m.). 
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This kind of formulation has already been proved in new-onset GCA with excellent 
results in comparison with immediate-release prednisone (93). 
Because of several case series have shown some potential benefit of leflunomide in 
patients with refractory PMR (61,94), we think that prospective evaluation of this agent 
in randomized controlled trials would be stimulating. 
6.6. Polymyalgia and immunotherapy 
Immune checkpoint inhibitors (ICI) are a family of agents highly effective in different 
types of tumors such as melanoma, lung cancer, metastatic renal cancer or malignant 
hematologic disorders. However, these agents also produce frequent undesirable side 
effects. In particular, it has been observed that anti CTLA-4 (ipilimumab) and anti PD-1 
(nivolumab or pembrolizumab) antibodies often produce immune-related adverse 
effects (IRAEs) or triggers flares of previous rheumatic diseases already known (95,96). 
Indeed, a broad spectrum of immune toxicities has been reported up to now such as 
sarcoidosis, polyarthritis, lupus, celiac disease, dermatomyositis, and also PMR and 
GCA (96). As well, new cases of PMR-type conditions have also been reported by other 
authors in patients under these therapies (97-99). Though, in a recent retrospective 
review performed to identify all patients who received ICI therapy at Mayo Clinic 
between 2011 and 2016, only 16 patients (five with PMR) experienced a flare of their 
preexisting rheumatic disease over around 700 patients treated (100). In general, cases 
of PMR and other IRAEs respond well to treatment with GCs and DMARDs. 
Conclusions 
PMR is a common inflammatory disease in people older than 50 years from Western 
countries. Glucocorticoids are the first line of therapy for PMR. However and due to the 
frequent occurrence of adverse events, GC-sparing agents are habitually required. 
Among them, MTX is the most commonly used conventional DMARD (Table 2). 
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Nonetheless, its effect to prevent relapses of the disease and to reduce the cumulative 
prednisone dose is often modest. Biologic agents have been used in patients with 
refractory disease or in those in whom GCs have to be discontinued due to adverse 
events. Randomized controlled trials do not support the use of anti-TNF agents in the 
management of PMR. In contrast, several case series and retrospective studies have 
highlighted the efficacy of the anti-IL-6R TCZ in PMR, although controlled trials 
including large series of patients to evaluate the efficacy of this agent in refractory PMR 
are needed. The potential positive effect of the JAK inhibitors in isolated PMR remains 
to be determined. The graphic abstract summarizes the main etiopathogenic, clinical 
and therapeutic aspects of polymyalgia rheumatica. 
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Figure 1. Ultrasonography of the left shoulder in a patient with polymyalgia 
rheumatica. Ultrasonographic images showing typical findings at periarticular soft 
tissues of the left shoulder. A. Longitudinal view of the subacromial/subdeltoid bursa. 
White asterisks represent the virtual cavity of the bursa filled with synovial fluid. B. 
Transverse view of biceps tendon with signs of inflammation and fluid around the 
tendon (white small arrows). C. Longitudinal view of biceps tendon showing signs of 
tenosynovitis (white asterisks inside the tendon sheath). Images obtained in our 
Outpatient Clinic. 
 
Figure 2. Schematic view for a stepped treatment of polymyalgia rheumatica. 
Footnotes: IL-6R: interleukin 6 receptor; JAK/STAT: Janus kinase/signal transducers 
and activators of transcription; OP: osteoporosis; TCZ: tocilizumab. 
 
GRAPHICAL ABSTRACT. Relationship of PMR with GCA and other related 
inflammatory diseases in the elderly.  
Footnotes: DMARDs: disease-modifying anti-rheumatic drugs; EORA: elderly-onset 
rheumatoid arthritis; IL: interleukins (1, 6, 8); MCP-1: monocyte chemoattractant 
protein 1; NSAIDs: non-steroidal anti-inflammatory drugs; PMR: polymyalgia 
rheumatica; RS3PE: remitting seronegative symmetrical synovitis with pitting oedema 
syndrome; TNF-α: tumor necrosis factor alpha; Th: T-helper (Th1, Th17) lymphocytes; 
Treg: regulatory T lymphocytes. The two images at the center bottom show a 
subacromial bursitis and tenosynovitis of the biceps in a patient with PMR. The one on 
the right at the middle exemplifies the “halo sign” in a temporal artery of a patient with 
giant cell arteritis. 
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Table 1. Symptoms, clinical features and imaging findings of PMR. 
___________________________________________________________ 
A) Inflammatory pain and stiffness in shoulders, hips or neck and¶: 
Age older than 50 years 
Pain in upper arms and/or thighs 
Morning stiffness > 45 minutes 
Rapid onset of manifestationsa  
Symptoms are usually bilateralb 
Restricted range of motionc 
Muscle tenderness in affected muscles  
Difficulty for basic activities of daily lifed 
Peripheral non-erosive arthritise 
Distal swelling and/or edema of hands 
 
B) Non-specific manifestations without evidence of infectious or neoplastic disease: 
 Low-grade fever 
Anorexia 
Weight loss (40-50% of cases) 
 Fatigue/malaise 
  
C) Unexplained anemia and elevated acute phase reactants, CRP and/or ESR: 
 ESR ≥ 40 mm/first hourf 
 CRP > 6 mg/L 
 
D) Other non-specific laboratory findings: 
 Thrombocytosis 
Increased levels of α-2 globulin  
Hypoalbuminemia 
Absence of RF and anti-CCP antibodiesg 
 
E) Imaging findings by US, MRI or PET/CT: 
Subacromial/subdeltoid bursitis 
Tenosynovitis of the biceps 
Glenohumeral synovitis 
Trochanteric or iliopsoas bursitis 
Cervical/lumbar interspinous bursitis 
Mild synovitis in peripheral joints 
Occult large vessel involvementh by PET/CT 
______________________________________________________________________ 
Abbreviations: PMR: polymyalgia rheumatica; ESR: erythrocyte sedimentation rate; CRP: C-
reactive protein RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; 
US: ultrasonography; MRI: magnetic resonance imaging; PET/CT: positron emission 
tomography integrated with computed tomography 
  
¶ In addition to one or several of the items included in this section.  
a The onset of symptoms is often rapid, generally over a few days and in some cases overnight. 
b Although symptoms can start alone on one side, clinical manifestations are later bilateral. 
c In all joints affected and near regions. 
d Such as dressing, washing, brushing hair, getting out of bed or rising from a chair. 
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e Typically, arthritis of patients with PMR is most commonly asymmetrical, mild, non-erosive 
and affects peripheral joints, particularly knees and wrists, appearing in 23-39% of the cases.   
f The initial erythrocyte sedimentation rate can be <40 mm/h in up to 20% of patients with PMR. 
g The presence of RF or anti-CCP antibodies forces to discard rheumatoid arthritis. 
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Table 2. Main drugs used or in progress in the management of polymyalgia rheumatica. 
__________________________________________________________________ 
1. Glucocorticoids (gold standard therapy): 
   - Most commonly prednisone/prednisolone oral: initial dose 12.5-25 mg/day. 
   - In patients of low weight or with complications such as diabetes or osteoporosis start 
with 12.5-15 mg/day. 
   - In obese or very symptomatic people without risk factors, start with 20-25 mg/day. 
   - Intramuscular methylprednisolone acetate (120 mg eow for 12 weeks followed by 
monthly injections with dose reductions of 20 mg every 3 months) is effective but less 
than standard regimen of oral prednisolone. 
   - Bilateral shoulder injections of 6-methylprednisolone every 4 wks in special cases*. 
2. Glucocorticoid-sparing agent (moderate efficacy)#: 
   - Methotrexate has only a modest effect as a steroid saver. 
   - The recommended dose of methotrexate is at least 10-15 mg preferably via 
parenteral. 
   - Leflunomide 10-20 mg/day has shown promising results in patients refractory to 
glucocorticoids.  
3. Biological agents:  
   - Anti-IL-6R tocilizumab# is the only biological agent that has shown utility to treat    
PMR, especially in relapsing patients. 
4. Therapies in research:  
 
   - Janus kinase inhibitors; other IL-6R antagonists 
________________________________________________________________ 
 
Abbreviations: PMR: polymyalgia rheumatica; IL-6R: interleukin 6 receptor; eow: 
every other week.  
*Especially in patients with severe subacromial/subdeltoid bursitis only as an adjuvant 
therapy at specific moments.  
#None of them currently approved for the treatment of PMR.  
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Table 3. Main adverse effects of prolonged use of glucocorticoids. 
____________________________________________________________ 
A) Musculoskeletal: 
      Osteoporosis 
      Steroid myopathy  
      Osteonecrosisa 
 
B) Metabolic/hormonal effects: 
      Diabetes and glucose intolerance 
      Body morphology disturbances 
      Adrenal suppression 
      Libido decrease 
      Hirsutism 
 
C) Cardiovascular system: 
      Hypertension 
      Dyslipidemia 
      Atherosclerosis and ischemic heart disease 
 
D) Immune system (infections): 
      Increased risk of general infections 
      Increased risk of opportunistic infection and herpes zoster 
 
E) Psychological: 
      Mood disturbances and psychosis 
      Insomnia 
 
F) Dermatological: 
      Acne, alopecia, capillary fragility 
      Skin atrophy  
 
G) Ocular: 
      Cataract, glaucoma 
 
H) Gastrointestinal: 
      Gastritis, peptic ulcer disease 
______________________________________________________________________ 
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